Endothelial nitric oxide synthase gene polymorphisms in Fabry's disease

Area of Science:

• Genetics
• Cardiovascular Diseases
• Rare Genetic Disorders

Background:

• Endothelial nitric oxide synthase (eNOS) gene variations are implicated in nitric oxide (NO) synthesis abnormalities, leading to vascular cell damage, particularly in endothelial cells (ECs).
• Fabry disease, caused by alpha-galactosidase A (alpha-gal A) gene mutations, results in glycosphingolipid accumulation in ECs, contributing to endothelial dysfunction.

Purpose of the Study:

• To investigate the association between eNOS gene polymorphisms (Glu298Asp variant and 4b/a tandem repeats) and Fabry disease.
• To determine if eNOS genetic variations contribute to the endothelial dysfunction in Fabry disease patients.

Main Methods:

• Genotyping of the eNOS Glu298Asp (G894T) variant and the eNOS 4b/a polymorphism in 19 Fabry disease patients and 39 healthy volunteers.
• Statistical analysis to compare genotype and allele frequencies between patients and controls.

Main Results:

• Significantly higher frequencies of mutant Glu/Asp + Asp/Asp genotypes (68.4%) and the Asp allele (47.4%) for the Glu298Asp variant were observed in Fabry disease patients compared to controls.
• Significantly different frequencies of eNOS 4b/a polymorphisms were found, with mutant 4b/a + 4a/a genotype (55.5%) and 4a allele (27.8%) being more prevalent in Fabry disease patients.
• Over half of Fabry disease patients carried at least one of the studied eNOS gene variants (Glu298Asp or 4b/a).

Conclusions:

• The study provides the first evidence suggesting an influence of eNOS gene polymorphisms on the pathophysiology of Fabry disease.
• These eNOS genetic variations may play a role in the endothelial dysfunction associated with Fabry disease.